Are Mammaprint and OncotypeDx as useful in stratifying risk in patients with early stage HR+, HER2 negative lobular carcinomas, as in those with ductal carcinomas?

OncotypDX is not very useful in stratifying patients with early stage HR+ HER 2 negative invasive lobular carcinoma. Several studies (MD Anderson, Penn State) have shown that only 1-2 % of invasive ILC cancers are classified as High risk therefore receiving strong recommendation for chemotherapy. Since the benefit of adjuvant chemo in the intermediate risk is still unclear, it follows that the Oncotype will give a strong recommendation for chemotherapy in only 1-2% of ILC. Approximately 33 to 55...